All News
Filter News
Found 809,002 articles
-
Trailblazing work with 3D Human Liver Models Yields Accurate MASH (formerly NASH) Phenotype
1/23/2024
Viscient Biosciences announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medical research institute, and Salk Institute, have published the first demonstration of a liver fibrosis phenotype in a 3D human tissue model of MASH demonstrating strong comparability to the native disease by multiple measures.
-
ONL Therapeutics to Present on ONL1204 in Podium Presentation at the 47th Annual Meeting of the Macula Society
1/23/2024
ONL Therapeutics, Inc. announced that David Zacks, M.D., Ph.D. and the Edna H. Perkiss will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.
-
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
1/23/2024
Rezolute, Inc. (Nasdaq: RZLT) today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, to RZ358 for the treatment of hypoglycemia due to congenital hyperinsulinism (HI).
-
GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease
1/23/2024
GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group.
-
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP
1/23/2024
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.
-
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
1/23/2024
Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson’s Research, a non-profit organization dedicated to finding a cure for Parkinson’s disease, announced a research project to accelerate research on genetic risk factors associated with PD, specifically targeting the role of variants in the GBA gene.
-
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections
1/23/2024
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I/II trial assessing the safety and efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), in patients with diabetic foot infections (DFI).
-
Johnson & Johnson Reports Q4 and Full-Year 2023 Results
1/23/2024
Johnson & Johnson announced results for fourth-quarter and full year 2023. “Johnson & Johnson’s full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer.
-
Sciwind Biosciences Announces Positive Results from Phase 1 Clinical Trial of XW004, an Oral Formulation of Long-acting GLP-1 Analog Ecnoglutide
1/23/2024
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive interim results from the first four cohorts of a Phase 1 clinical trial of oral ecnoglutide (XW004).
-
PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors
1/23/2024
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on next-generation antibody therapeutics, announced today the initiation of patient dosing in the Phase 1a/b clinical trial of PMC-309 in patients with advanced or metastatic solid tumors.
-
Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts
1/23/2024
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced the operational readiness of its new proteomics facility in Massachusetts.
-
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)
1/23/2024
GC Biopharma Corp. announced that the European Medicines Agency has granted Orphan Drug Designation to its intracerebroventricular Enzyme Replacement Therapy candidate, GC1130A, designed for Sanfilippo Syndrome type A, developed in collaboration with Novel Pharma.
-
BD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics
1/23/2024
BD announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.
-
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
1/23/2024
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for the Company’s product candidate aerosolized 4D-710 for treatment of cystic fibrosis (CF) lung disease.
-
IAOMT Position Paper Examines the Science of Jawbone Cavitations Just Ahead of the Yankee Dental Congress!
1/23/2024
The International Academy of Oral Medicine and Toxicology is pleased to announce the publication of its new position paper on Human Jawbone Cavitations.
-
Caris Life Sciences to Present Research at the 2024 ASCO Genitourinary Cancers Symposium
1/23/2024
Caris Life Sciences® announced that the company and collaborators within the Caris Precision Oncology Alliance™ will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco.
-
3M Delivers Strong Fourth-Quarter Results; Improves Operational Performance and Exceeds Earnings and Cash Flow Expectations
1/23/2024
3M reported fourth-quarter and full-year 2023 results and provided its 2024 financial outlook.
-
Unnatural Products, Inc. Enters Research Collaboration with Merck Merck to leverage UNP’s cell permeability capabilities
1/23/2024
Unnatural Products, Inc. (UNP) today announced a collaboration withMerck, known as MSD outside the United States and Canada, to apply UNP’s technology to design and develop macrocyclic candidates against an oncology therapeutic target.
-
Axena Health Commends New Study Showing the Leva System’s Long-term Treatment Efficacy for Female Urinary Incontinence
1/23/2024
Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).
-
CardioSignal Raises $10 Million in Series A as the First Technology to Detect Major Heart Diseases without Specialized Medical Hardware
1/23/2024
CardioSignal announced the closing of $10 million in Series A funding, led by DigiTx Partners, with participation from Sandwater and existing investor Maki.vc. David J. Kim, M.D., managing director of DigiTx, will be joining the board.